Antitumor effect of pyrrolo-1,5-benzoxazepine-15 and its synergistic effect with Oxaliplatin and 5-FU in colorectal cancer cells

References

• Haggar FA, Boushey RP. Colorectal cancerepidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg 2009; 22:191-7; PMID:21037809; http://dx.doi.org/10.1055/s-0029-1242458
   PubMedGoogle Scholar
• Wada-Hiraike O, Warner M, Gustafsson JA. New developments in oestrogen signalling in colonic epithelium. Biochem Soc Trans 2006; 34(Pt 6):1114-6; PMID:17073763; http://dx.doi.org/10.1042/BST0341114
   PubMed Web of Science ®Google Scholar
• Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005; 352:476-87; http://dx.doi.org/10.1056/NEJMra040958
   PubMed Web of Science ®Google Scholar
• Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, Levitt R, Rowland K, Nair S, Sargent DJ, et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group Phase II Study. J Cli Oncol 2005; 23: 9243-9; http://dx.doi.org/10.1200/JCO.2005.07.740
   PubMed Web of Science ®Google Scholar
• Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T, Debraud F, Figer A, Grossmann J, Sawada N, et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004; 22:2084-91; http://dx.doi.org/10.1200/JCO.2004.11.069
   PubMed Web of Science ®Google Scholar
• André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, et al. Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350:2343-51; http://dx.doi.org/10.1056/NEJMoa032709
   PubMed Web of Science ®Google Scholar
• Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22:23-30; http://dx.doi.org/10.1200/JCO.2004.09.046
   PubMed Web of Science ®Google Scholar
• Zhang N, Yin Y, Xu SJ, Chen WS. 5-Fluorouracil: mechanisms of resistance and reversal strategies. Molecules 2008; 13:1551-69; PMID:18794772; http://dx.doi.org/10.3390/molecules13081551
   PubMed Web of Science ®Google Scholar
• Malfitano AM, Ciaglia E, Gangemi G, Gazzerro P, Laezza C, Bifulco M. Update on the endocannabinoid system as an anticancer target. Expert Opin Ther Targets 2011; 15:297-308; http://dx.doi.org/10.1517/14728222.2011.553606
   PubMed Web of Science ®Google Scholar
• Pisanti S, Picardi P, D'Alessandro A, Laezza C, Bifulco M. The endocannabinoid signaling system in cancer.Trends Pharmacol Sci 2013; 34:273-82; PMID:23602129; http://dx.doi.org/10.1016/j.tips.2013.03.003
   PubMed Web of Science ®Google Scholar
• Guida M, Ligresti A, De Filippis D, D'Amico A, Petrosino S, Cipriano M, Bifulco G, Simonetti S, Orlando P, Insabato L, et al. The levels of the endocannabinoid receptor CB2 and its ligand 2-arachidonoylglycerol are elevated in endometrial carcinoma. Endocrinology 2010; 151:921-8; PMID:20133454; http://dx.doi.org/10.1210/en.2009-0883
   PubMed Web of Science ®Google Scholar
• Proto MC, Gazzerro P, Di Croce L, Santoro A, Malfitano AM, Pisanti S, Laezza C, Bifulco M. Interaction of endocannabinoid system and steroid hormones in the control of colon cancer cell growth. J Cell Physiol 2012; 227:250-8; PMID:21412772; http://dx.doi.org/10.1002/jcp.22727
   PubMed Web of Science ®Google Scholar
• Izzo AA, Aviello G, Petrosino S, Orlando P, Marsicano G, Lutz B, Borrelli F, Capasso R, Nigam S, Capasso F, et al. Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon. J MolMed (Berl) 2008; 86:89-98; PMID:17823781
   PubMed Web of Science ®Google Scholar
• Ligresti A, Bisogno T, Matias I, De Petrocellis L, Cascio MG, Cosenza V, D'argenio G, Scaglione G, Bifulco M, Sorrentini I, et al. Possible endocannabinoid control of colorectal cancer growth. Gastroenterology 2003; 125:677-87; PMID:12949714; http://dx.doi.org/10.1016/S0016-5085(03)00881-3
   PubMed Web of Science ®Google Scholar
• Notarnicola M, Messa C, Orlando A, Bifulco M, Laezza C, Gazzerro P, Caruso MG. Estrogenic induction of cannabinoid CB1 receptor in human colon cancer cell lines. Scand J Gastroenterol 2008; 43:66-72; PMID:18938775; http://dx.doi.org/10.1080/00365520701559011
   PubMed Web of Science ®Google Scholar
• Campiani G, Nacci V, Fiorini I, De Filippis MP, Garofalo A, Ciani SM, Greco G, Novellino E, Williams DC, Zisterer DM, et al. Synthesis, biological activity, and SARs of pyrrolobenzoxazepine derivatives, a new class of specific “peripheral-type” benzodiazepine receptor ligands. J Med Chem 1996; 39:3435-50; PMID:8784441; http://dx.doi.org/10.1021/jm960251b
   PubMed Web of Science ®Google Scholar
• Mulligan JM, Greene LM, Cloonan S, Mc Gee MM, Onnis V, Campiani G, Fattorusso C, Lawler M, Williams DC, Zisterer DM. Identification of tubulin as the molecular target of proapoptotic pyrrolo-1,5-benzoxazepines. MolPharmacol 2006; 70:60-70
   PubMed Web of Science ®Google Scholar
• Greene LM, Campiani G, Lawler M, Williams DC, Zisterer DM. BubR1 is required for a sustained mitotic spindle checkpoint arrest in human cancer cells treated with tubulin-targeting pyrrolo-1,5-benzoxazepines. Mol Pharmacol 2008; 73:419-30
   PubMed Web of Science ®Google Scholar
• McElligott AM, Maginn EN, Greene LM, McGuckin S, Hayat A, Browne PV, Butini S, Campiani G, Catherwood MA, Vandenberghe E, et al. The novel tubulin-targeting agent pyrrolo-1,5-benzoxazepine-15 induces apoptosis in poor prognostic subgroups of chronic lymphocytic leukemia. Cancer Res 2009; 69:8366-75; PMID:19826055; http://dx.doi.org/10.1158/0008-5472.CAN-09-0131
   PubMed Web of Science ®Google Scholar
• Nathwani SM, Butler S, Fayne D, McGovern NN, Sarkadi B, Meegan MJ, Lloyd DG, Campiani G, Lawler M, Williams DC, et al. Novel microtubule-targeting agents, pyrrolo-1,5-benzoxazepines, induce apoptosis in multi-drug-resistant cancer cells. Cancer Chemother Pharmacol 2010; 66:585-96
   PubMed Web of Science ®Google Scholar
• Bright SA, McElligott AM, O'Connell JW, O'Connor L, Carroll P, Campiani G, Deininger MW, Conneally E, Lawler M, Williams DC, et al. Novel pyrrolo-1,5-benzoxazepine compounds display significant activity against resistant chronic myeloid leukaemia cells in vitro, in ex vivo patient samples and in vivo. Br J Cancer 2010; 102:1474-82; PMID:20407438; http://dx.doi.org/10.1038/sj.bjc.6605670
   PubMed Web of Science ®Google Scholar
• Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22:27-55; PMID:6382953; http://dx.doi.org/10.1016/0065-2571(84)90007-4
   PubMedGoogle Scholar
• Takahashi N, Li W, Banerjee D, Guan Y, Wada-Takahashi Y, Brennan MF, Chou TC, Scotto KW, Bertino JR. Sequence-dependent synergistic cytotoxicity of ecteinascidin-743 and paclitaxel in human breast cancer cell lines in vitro and in vivo. Cancer Res 2002; 62:6909-15; PMID:12460906
   PubMed Web of Science ®Google Scholar
• Bifulco M, Di Marzo V. Targeting the endocannabinoid system in cancer therapy: a call for further research. Nat Med 2002; 8:547-50; PMID:12042794; http://dx.doi.org/10.1038/nm0602-547
   PubMed Web of Science ®Google Scholar
• Hamtiaux L, Hansoulle L, Dauguet N, Muccioli GG, Gallez B, Lambert DM. Increasing antiproliferative properties of endocannabinoids in N1E-115 neuroblastoma cells through inhibition of their metabolism. PLoS One 2011; 6:e26823; http://dx.doi.org/10.1371/journal.pone.0026823
   PubMed Web of Science ®Google Scholar
• Hamtiaux L, Masquelier J, Muccioli GG, Bouzin C, Feron O, Gallez B, Lambert DM. The association of N-palmitoylethanolamine with the FAAH inhibitor URB597 impairs melanoma growth through a supra-additive action. BMC Cancer 2012; 12:92; PMID:22429826; http://dx.doi.org/10.1186/1471-2407-12-92
   PubMed Web of Science ®Google Scholar
• Ravi J, Sneh A, Shilo K, Nasser MW, Ganju RK. FAAH inhibition enhances anandamide mediated anti-tumorigenic effects in non-small cell lung cancer by downregulating the EGF/EGFR pathway. Oncotarget 2014; 5:2475-86; PMID:24811863; http://dx.doi.org/10.18632/oncotarget.1723
   PubMed Web of Science ®Google Scholar
• Greene LM, Nolan DP, Regan-Komito D, Campiani G, Williams DC, Zisterer DM. Inhibition of late-stage autophagy synergistically enhances pyrrolo-1,5-benzoxazepine-6-induced apoptotic cell death in human colon cancer cells. Int J Oncol 2013; 43:927-35; PMID:23799546
   PubMed Web of Science ®Google Scholar
• Lu C, Zhu F, Cho YY, Tang F, Zykova T, Ma WY, Bode AM, Dong Z. Cell apoptosis: requirement of H2AX in DNA ladder formation, but not for the activation of caspase-3. Mol Cell 2006; 23:121-32; PMID:16818236; http://dx.doi.org/10.1016/j.molcel.2006.05.023
   PubMed Web of Science ®Google Scholar
• Lysaght J, Verma NK, Maginn EN, Ryan JM, Campiani G, Zisterer DM, Williams DC, Browne PV, Lawler MP, McElligott AM. The microtubule targeting agent PBOX-15 inhibits integrin-mediated cell adhesion and induces apoptosis in acute lymphoblastic leukaemia cells. Int J Oncol 2013; 42:239-46; PMID:23135704
   PubMed Web of Science ®Google Scholar
• Maginn EN, Browne PV, Hayden P, Vandenberghe E, MacDonagh B, Evans P, Goodyer M, Tewari P, Campiani G, Butini S, et al. PBOX-15, a novel microtubule targeting agent, induces apoptosis, upregulates death receptors, and potentiates TRAIL-mediated apoptosis in multiple myeloma cells. Br J Cancer 2011; 104:281-89; PMID:21179037; http://dx.doi.org/10.1038/sj.bjc.6606035
   PubMed Web of Science ®Google Scholar
• Sui X, Kong N, Ye L, Han W, Zhou J, Zhang Q, He C, Pan H. p38 and JNK MAPK pathways control the balance of apoptosis and autophagy in response to chemotherapeutic agents. Cancer Lett 2014; 344:174-79; PMID:24333738; http://dx.doi.org/10.1016/j.canlet.2013.11.019
   PubMed Web of Science ®Google Scholar
• Wada T, Penninger JM. Mitogen-activated protein kinases in apoptosis regulation. Oncogene 2004; 23:2838-49; PMID:15077147; http://dx.doi.org/10.1038/sj.onc.1207556
   PubMed Web of Science ®Google Scholar
• Dey H, Liu ZR. Phosphorylation of p68 RNA helicase by p38 MAP kinase contributes to colon cancer cells apoptosis induced by oxaliplatin. BMC Cell Biol 2012; 13:27; PMID:23110695; http://dx.doi.org/10.1186/1471-2121-13-27
   PubMed Web of Science ®Google Scholar
• de la Cruz-Morcillo MA, Valero ML, Callejas-Valera JL, Arias-González L, Melgar-Rojas P, Galán-Moya EM, García-Gil E, García-Cano J, Sánchez-Prieto R. P38MAPK is a major determinant of the balance between apoptosis and autophagy triggered by 5-fluorouracil: implication in resistance. Oncogene 2012; 31:1073-85; PMID:21841826; http://dx.doi.org/10.1038/onc.2011.321
   PubMed Web of Science ®Google Scholar
• Violette S, Poulain L, Dussaulx E, Pepin D, Faussat AM, Chambaz J, Lacorte JM, Staedel C, Lesuffleur T. Resistance of colon cancer cells to long-term 5-fluorouracil exposure is correlated to the relative level of Bcl-2 and Bcl-X(L) in addition to Bax and p53 status. Int J Cancer 2002; 98:498-504; PMID:11920608; http://dx.doi.org/10.1002/ijc.10146
   PubMed Web of Science ®Google Scholar